Watch for Ensifentrine (Ohtuvayre) for COPD
September 2024
Ensifentrine (Ohtuvayre), a new nebulized med for COPD maintenance therapy in adults, will pop up on some home med lists.
It’s the first dual phosphodiesterase 3 (PDE3) AND phosphodiesterase 4 (PDE4) inhibitor...that bronchodilates and reduces inflammation.
Evidence shows ensifentrine improves lung function more than placebo. But over half of patients were on a long-acting beta-agonist (LABA) OR long-acting muscarinic antagonist (LAMA)...with or without an inhaled corticosteroid (ICS).
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote